China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third quarter of 2024, announcing revenues of RMB 135 million (USD 18.94 million) for the quarter, marking a 236.39% year-on-year (YOY) increase. Revenues for the first three quarters reached RMB 338 million (USD 47.43 million), reflecting a substantial 743.97% YOY growth.
The company’s market presence is bolstered by two key products: sunvozertinib, a next-generation epidermal growth factor receptor (EGFR) inhibitor approved in China in August of the previous year for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR Exon20ins mutations in patients who have been previously treated with platinum chemotherapy or are intolerant of platinum. Sunvozertinib has received four breakthrough therapy designations (BTDs) in China and the US for the full-line treatment of EGFR Exon20ins NSCLC. The other product, golidocitinib, is the first and only approved Janus kinase 1 (JAK1) selective inhibitor for relapsed or refractory (r/r) peripheral T-Cell lymphoma (PTCL) patients globally, following its marketing approval in China in June this year. Dizal is working towards including both drugs in China’s National Reimbursement Drug List (NDRL).- Flcube.com
